Profiling of Circulating Tumor Cells for Screening of Selective Inhibitors of Tumor-Initiating Stem-Like Cells.

Adv Sci (Weinh) · 2023 · PMC10190641 · PMID 36949364

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

[ 47 ] This combination therapy showed a trend of marginally higher CR rate (8.6% vs 4.9%, ns.), ORR (22.4% vs 19.5%, ns.) compared to anti‐PD‐1 alone, [ 47 ] but there was a significant number of therapy refractory patients.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.